Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$10.39
-1.0%
$10.37
$3.85
$12.43
$1.58B1.831.64 million shs1.44 million shs
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$3.23
+15.8%
$2.26
$1.03
$3.35
$647.09M1.442.17 million shs14.82 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.75
+1.5%
$17.97
$13.53
$35.25
$2.09B2.071.57 million shs2.16 million shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$15.69
-1.7%
$13.17
$9.00
$19.09
$2.10B1.45772,953 shs1.01 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-3.05%-13.08%+3.55%+43.25%+141.38%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
+3.33%+2.20%+25.68%+89.80%+74.38%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+1.89%-7.17%+22.68%+20.29%-24.06%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
+1.98%+8.94%+26.67%+29.76%+67.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.7889 of 5 stars
1.41.00.04.22.72.50.6
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.2147 of 5 stars
3.84.00.00.02.51.70.6
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.0678 of 5 stars
3.50.00.00.02.52.50.6
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3.4103 of 5 stars
3.54.00.00.02.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.86
Moderate Buy$10.571.75% Upside
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.50
Strong Buy$9.00178.64% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$48.75134.94% Upside
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3.00
Buy$27.8977.75% Upside

Current Analyst Ratings Breakdown

Latest ATAI, ADPT, CNTA, and BEAM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Aegis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $12.00
6/18/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
5/28/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$5.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Outperform$6.00
5/8/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $55.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$178.96M8.82N/AN/A$1.37 per share7.58
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$1.86M347.34N/AN/A$0.69 per share4.68
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M32.85N/AN/A$8.86 per share2.34
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$6.85M305.90N/AN/A$3.05 per share5.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%8/5/2025 (Estimated)
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)

Latest ATAI, ADPT, CNTA, and BEAM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.13N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.34N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.24N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04N/AN/AN/A$13.29 millionN/A
5/14/2025Q1 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/12/2025Q1 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.20+$0.15-$0.20N/AN/A
5/6/2025Q1 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million
5/1/2025Q1 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.92
2.82
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.08
4.07
4.07
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
8.81
8.81
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.28
14.37
14.37

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790151.92 million142.19 millionOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80200.34 million146.65 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510100.56 million97.04 millionOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200133.55 million124.09 millionOptionable

Recent News About These Companies

CNTA Centessa Pharmaceuticals plc - Seeking Alpha
Centessa announces clearance of IND for ORX142

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$10.39 -0.11 (-1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$10.62 +0.23 (+2.21%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$3.23 +0.44 (+15.77%)
Closing price 04:00 PM Eastern
Extended Trading
$3.24 +0.02 (+0.46%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$20.75 +0.30 (+1.47%)
Closing price 04:00 PM Eastern
Extended Trading
$20.88 +0.13 (+0.60%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$15.69 -0.27 (-1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$15.68 -0.01 (-0.10%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.